Diamond Hill Capital Management LLC Investment Advisor Purchases 629,974 Shares of Zoetis Inc. $ZTS

Diamond Hill Capital Management LLC Investment Advisor grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 21.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,557,436 shares of the company’s stock after buying an additional 629,974 shares during the period. Zoetis comprises 2.0% of Diamond Hill Capital Management LLC Investment Advisor’s portfolio, making the stock its 10th largest position. Diamond Hill Capital Management LLC Investment Advisor owned 0.85% of Zoetis worth $255,637,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ZTS. RFG Advisory LLC raised its position in shares of Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after acquiring an additional 80 shares in the last quarter. Quest 10 Wealth Builders Inc. boosted its holdings in Zoetis by 4.7% in the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after purchasing an additional 86 shares during the period. Financial Engines Advisors L.L.C. boosted its holdings in Zoetis by 4.4% in the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after purchasing an additional 87 shares during the period. Physician Wealth Advisors Inc. increased its stake in Zoetis by 17.4% during the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after purchasing an additional 91 shares during the last quarter. Finally, Smithfield Trust Co raised its holdings in shares of Zoetis by 4.2% during the fourth quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock worth $290,000 after purchasing an additional 92 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 0.2%

Shares of NYSE:ZTS opened at $73.64 on Monday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The company’s 50-day moving average price is $76.30 and its 200 day moving average price is $98.84. The company has a market cap of $30.43 billion, a PE ratio of 12.13, a P/E/G ratio of 1.28 and a beta of 0.73. Zoetis Inc. has a fifty-two week low of $71.45 and a fifty-two week high of $160.48.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the prior year, the firm earned $1.76 EPS. Zoetis’s quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. Zoetis’s payout ratio is currently 34.93%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. William Blair restated a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. Citigroup lowered their price objective on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research note on Friday, June 26th. TD Cowen cut their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. Finally, Zacks Research downgraded Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $109.62.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.